Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized Double-blind, Placebo-controlled, Multicenter Study of SHR-1701 in Combination With Bevacizumab and Chemotherapy in Advanced or Metastatic Non-squamous Non-small-cell Lung Cancer With EGFR Mutation After Failure of TKIs
Conditions
Interventions
SHR-1701 + Pemetrexed Disodium + cisplatin/carboplatin + bevacizumab
Placebo + SHR-1701 + Pemetrexed Disodium+ cisplatin/carboplatin
+1 more
Start Date
December 30, 2021
Primary Completion Date
December 30, 2024
Completion Date
December 30, 2024
Last Updated
November 24, 2021
Lead Sponsor
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions